HealthcareServices

Cutaneous Squamous Cell Carcinoma (cSCC) Market Outlook: Growth and Forecast Highlights 2030

February 23, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cutaneous squamous cell carcinoma (cscc) market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Cutaneous Squamous Cell Carcinoma (cSCC) Market show for the 2026–2030 period?

The market size for cutaneous squamous cell carcinoma (cscc) has shown substantial growth in recent years. It is anticipated to increase from $7.87 billion in 2025 to $8.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.8%. This historical expansion can be attributed to high UV exposure rates, the rising aging population, heightened awareness of skin cancer, the reliance on surgical excision, and the availability of hospital-based oncology care.

The market for cutaneous squamous cell carcinoma (cscc) is projected to experience robust expansion over the coming years, anticipated to reach $10.35 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. This growth during the forecast period can be attributed to several factors, including advancements in skin cancer diagnostic methods, increasing preference for outpatient procedures, the expansion of dermatologic oncology facilities, better availability of early detection methods, and the creation of targeted therapeutic approaches. Key trends expected during this period involve the increasing uptake of Mohs micrographic surgery, a greater reliance on non-surgical treatments, the development of early skin cancer screening programs, broader access to outpatient cancer care, and an emphasis on minimally invasive medical interventions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21163&type=smp

What Drivers Are Shaping The Development Of The Cutaneous Squamous Cell Carcinoma (cSCC) Market?

Increasing recognition of skin cancer is anticipated to drive expansion in the cutaneous squamous cell carcinoma (cSCC) market moving ahead. Skin cancer involves the irregular proliferation of skin cells, frequently triggered by too much UV radiation, with severity varying from benign to fatal. This heightened awareness stems from expanded public health initiatives, better availability of information, and an increasing focus on prompt diagnosis and preventive measures, consequently boosting the need for diagnostic and therapeutic options. Cutaneous squamous cell carcinoma (cSCC) plays a vital role in advancing skin cancer care by facilitating specific treatments, refining diagnostic processes, and elevating patient results, thereby contributing to more effective disease control. As an illustration, in January 2024, the American Cancer Society, a US non-profit focused on cancer eradication, reported 104,930 skin cancer cases in 2023, showing a 3.2% rise from the 108,270 cases documented in 2022. Consequently, the increasing awareness of skin cancer is expected to stimulate growth within the cutaneous squamous cell carcinoma (cSCC) market.

What Segment Types Are Examined In The Cutaneous Squamous Cell Carcinoma (cSCC) Market?

The cutaneous squamous cell carcinoma (cscc) market covered in this report is segmented –

1) By Treatment: Surgical Treatment, Non-Surgical Treatment

2) By Diagnosis: Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Biopsy

3) By Application: Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Other Applications

Subsegments:

1) By Surgical Treatment: Excisional Surgery, Mohs Micrographic Surgery, Curettage And Electrodessication

2) By Non-Surgical Treatment: Radiation Therapy, Cryotherapy, Photodynamic Therapy, Topical Therapies, Systemic Therapies

What Industry Trends Are Transforming The Cutaneous Squamous Cell Carcinoma (cSCC) Market?

Leading companies in the cutaneous squamous cell carcinoma (cSCC) market are concentrating on advancements in immuno-oncology therapies, such as PD-L1 inhibitors and targeted treatments, to enhance patient outcomes and deliver effective solutions for managing advanced skin cancer. Programmed death-ligand 1 (PD-L1) is a protein that suppresses the immune response by binding to PD-1 receptors on T-cells, enabling cancer cells to evade immune detection. For instance, in December 2024, Checkpoint Therapeutics Inc., a US-based biotech company, secured FDA approval for Unloxcyt (cosibelimab-ipdl). This innovation functions by blocking PD-L1, thereby improving the immune system’s capacity to fight cancer and offering a safer, more effective treatment option. Moreover, its dual mechanisms of action present a promising strategy for managing advanced cutaneous squamous cell carcinoma (cSCC). The approval was founded on results from the CK-301-101 trial, which displayed clinically significant objective response rates and durable responses in patients with advanced cSCC.

Who Are The Major Companies Operating In The Cutaneous Squamous Cell Carcinoma (cSCC) Market?

Major companies operating in the cutaneous squamous cell carcinoma (cscc) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., Vidac Pharma Inc., Pfizer Inc., AstraZeneca plc, AbbVie Inc., Johnson & Johnson, Bayer AG, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cutaneous-squamous-cell-carcinoma-cscc-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Cutaneous Squamous Cell Carcinoma (cSCC) Market?

North America was the largest region in the cutaneous squamous cell carcinoma (CSCC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cutaneous squamous cell carcinoma (cscc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cutaneous Squamous Cell Carcinoma (cSCC) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21163&type=smp

Browse Through More Reports Similar to the Global Cutaneous Squamous Cell Carcinoma (cSCC) Market 2026, By The Business Research Company

Skin Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Basal Cell Carcinoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/basal-cell-carcinoma-treatment-global-market-report

Non Small Cell Lung Cancer Nsclc Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795